KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Shares Outstanding (Diluted Average) (2016 - 2025)

Neogenomics' Shares Outstanding (Diluted Average) history spans 14 years, with the latest figure at $128.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 1.14% year-over-year to $128.1 million; the TTM value through Dec 2025 reached $128.1 million, up 1.14%, while the annual FY2025 figure was $128.1 million, 1.14% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $128.1 million in Q4 2025 per NEO's latest filing, roughly flat from $127.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $130.2 million in Q2 2021 to a low of $116.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $125.2 million, with a median of $125.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 22.63% in 2021, then dropped 4.74% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $120.0 million in 2021, then grew by 3.55% to $124.2 million in 2022, then grew by 1.03% to $125.5 million in 2023, then grew by 0.92% to $126.7 million in 2024, then rose by 1.14% to $128.1 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Shares Outstanding (Diluted Average) are $128.1 million (Q4 2025), $127.9 million (Q3 2025), and $127.9 million (Q2 2025).